HOME > BUSINESS
BUSINESS
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
- Opdivo Price Cut Won’t Have Much Impact on Financial Results: Ono
August 27, 2018
- Pfizer, Astellas Move UP Completion Dates for 2 Xtandi Studies
August 24, 2018
- Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
August 24, 2018
- Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
August 24, 2018
- Lenvima Approved for 1st Line HCC Use in Europe: Eisai/Merck
August 24, 2018
- Shire Japan, Medipal Introduce Emergency Delivery System for Hemophilia Treatment
August 23, 2018
- MSD Launches Antibacterial Agent Sivextro
August 23, 2018
- Takeda, Ono Join Hands in Japan PIII for Opdivo-Cabozantinib Combo
August 23, 2018
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- Otsuka Grabs Rights to Osaka Univ. CAR-T Therapy
August 22, 2018
- Daiichi Sankyo Espha Unveils Authorized Generic Pact with AstraZeneca, 3 More Oncology AGs Pending Approval
August 21, 2018
- New Anti-Parkinson’s Drug Obtains POC in PIIa Study: Kyowa Kirin
August 21, 2018
- Japanese OTC Drug Market Grew 1.0% to 828 Billion Yen in 2017: Yano Research
August 21, 2018
- Japan’s 1st Herceptin Biosimilar Now Available, but Use Limited to Gastric Cancer
August 21, 2018
- Mitsubishi Tanabe Going Digital to Shed Drug Discovery and Sales Outlays: President
August 21, 2018
- I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
August 20, 2018
- Roche Diagnostics’ EGFR Mutations Test Kit Approved for Determining 1st Line Treatment of Tagrisso
August 20, 2018
- Solasia Licenses PTCL Treatment to Columbia Firm in Latin America
August 20, 2018
- Taiho Files Lonsurf for Gastric Cancer in Japan
August 20, 2018
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
